WENA: anewmeds.com Market Cap to Revenue Ratio
Anew Medical, Inc. (WENA) is optimizing expenses by outsourcing vector production, while its unique patents protect the company from pricing pressure. The P/S multiple chart allows for the determination of fair valuation ranges, where the 0.00 indicator expresses the state of the metric. Anew Medical, Inc. (WENA) aims to halt neurodegeneration by creating innovative gene therapies to combat Parkinson's and Alzheimer's diseases.
Metric breakdowns and analytics for Anew Medical, Inc. (WENA)
- current quotes and average value forecast:
- market capitalization information:
- business book valuation details:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
WENA - Net Profit|Future Profit Anew Medical, Inc.|WENA - Price to Earnings Ratio|Market Cap to Projected Earnings Anew Medical Inc.|WENA - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Anew Medical|WENA - Operating profit EBITDA|Net earnings per one share for the last twelve months Anew Medical|WENA - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months anewmeds.com|WENA - Earnings growth in current year|Earnings growth forecast for next year Anew Medical, Inc.
- issuer revenue and sales details:
Summary company analytics:Anew Medical Inc., WENA
The specifics of developing neurological disease therapies amidst geopolitical instability and logistical disruptions make Anew Medical, Inc. (WENA) revenue a key indicator of viability. By analyzing the price-to-sales ratio, an investor assesses the business's market value relative to sales volumes, which allows for determining the extent of overpayment for the asset or identifying the company's undervaluation across different phases of the economic cycle.
Competing companies
BIIB - Price to Sales|P/S Multiple NBIX (Neurocrine Biosciences, Inc.)|RGC: Market Cap to Revenue Ratio|Axsome Therapeutics Inc - P/S Multiple|Price-to-Revenue Coefficient ACADIA Corp ACAD|XENE: P/S Multiple|Market Cap to Revenue vikingtherapeutics.com|SUPN (Supernus) - P/S Multiple|P/S Multiple Catalyst Pharma|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|Price-to-Revenue Ratio HRMY (Harmony Corp)|Biohaven Ltd. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio AMLX|Trevi Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient Praxis Precision Medicines Inc PRAX|Anavex Corp (AVXL) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CBLL|PRTA (Prothena Biosciences) - P/S Multiple|Market Cap to Revenue Alector Therapeutics (ALEC)|Market Cap to Revenue ANNX (Annexon)|Price-to-Revenue Coefficient omeros.com|Neurogene Corp - Market Cap to Revenue|ACIU - Market Cap to Revenue|Voyager Therapeutics - P/S Multiple|Price to Sales neumoratx.com|Scilex (SCLX) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio TVGN|ACOG (Alpha Cognition Inc) - P/S Multiple|P/S Multiple Cognition Therapeutics Inc.|Price-to-Revenue Ratio Inhibikase Therapeutics (IKT)|cassavasciences.com - Market Cap to Revenue Ratio|P/S Multiple ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Price to Sales|VTGN: Market Cap to Revenue|OVID - P/S Multiple|Acumen Pharmaceuticals (ABOS) - Price-to-Revenue Ratio|cervomed.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|Price to Sales Clene Nanomedicine CLNN|P/S Multiple PEPG|P/S Multiple Jupiter Neurosciences, Inc. (JUNS)|Price-to-Revenue Ratio Relmada Therapeutics RLMD|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|Price to Sales Firefly Neuroscience, Inc.|KLTO (anewmeds.com) - Market Cap to Revenue|Market Cap to Revenue NeuroSense Therapeutics Ltd.|Market Cap to Revenue RVPH|MTVA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio NeurAxis (NRXS)|Market Cap to Revenue heliusmedical.com HSDT|P/S Multiple PASG (Passage Bio)|Neuphoria Therapeutics, Inc. (NEUP) - Price to Sales|Minerva Neurosciences - P/S Multiple|ATHA (athira.com) - Market Cap to Revenue Ratio|ADXN: P/S Multiple|ALZN - Price-to-Revenue Coefficient|CYCN (Cyclerion Therapeutics Inc.) - P/S Multiple|Market Cap to Revenue Protagenic (PTIX)|P/S Multiple KTTA|P/S Multiple cortigent.com (CRGT)|Price-to-Revenue Ratio Avenue Therapeutics, Inc. ATXI|Brainstorm Cell Therapeutics Inc. - Price-to-Revenue Ratio|CARA: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CHRO (Chromocell)|ELYM: P/S Multiple|ITCI - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Longboard Pharmaceuticals, Inc.|Market Cap to Revenue Ratio MRNS (Marinus Pharmaceuticals Inc)|P/S Multiple NKGN|Market Cap to Revenue NeuroBo Pharma NRBO|Sage Therapeutics, Inc. - Market Cap to Revenue|Price-to-Revenue Coefficient synaptogen.com (SNPX)|TRVN: Market Cap to Revenue|Vigil Neuroscience (VIGL) - Market Cap to Revenue|CERE: P/S Multiple
